Global Glimepiride Dispersible Tablet Market Size To Worth USD 2.15 Billion By 2033 | CAGR of 7.43%
Category: HealthcareGlobal Glimepiride Dispersible Tablet Market Worth USD 2.15 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Glimepiride Dispersible Tablet Market Size is Expected to Grow from USD 1.05 Billion in 2023 to USD 2.15 Billion by 2033, at a CAGR of 7.43% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 276 pages with 110 Market data tables and figures & charts from the report on the "Global Glimepiride Dispersible Tablet Market Size, Share, and COVID-19 Impact Analysis, By Dosage Strength (1mg, 2mg, 3mg, 4mg, and Others), By Application (Type 1 Diabetes, Type 2 Diabetes, and Others), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/glimepiride-dispersible-tablet-market
The glimepiride dispersible tablet market is a pharmaceutical industry that develops, produces, and commercializes tablets for managing type-2 diabetes with swallowing difficulties. Glimepiride is an anti-diabetic drug that lowers blood sugar levels by alleviating insulin levels. Its mechanism involves inhibiting ATP-dependent potassium channels, activating voltage-dependent calcium channels, and leading to exocytosis of insulin into the bloodstream. Glimepiride is an excellent drug for oral administration due to its low dose and tastelessness, making it a premium option for patients with dysphagia. The increasing prevalence of diabetes worldwide has led to a growing demand for anti-diabetic medications, leading to the expansion of the glimepiride market. Technological developments in drug formulation and manufacturing methods, such as taste-masking technologies and improved bioavailability, are facilitating market expansion. Government policies and regulatory approvals also contribute to market expansion. In 2021, 38.4 million Americans had diabetes, and 29.7 million had been diagnosed with diabetes. Type 2 diabetes, caused by insulin resistance, is prevalent due to factors like sedentary lifestyles, genetics, obesity, and poor diet. The geriatric population is at higher risk, leading to increased demand for anti-diabetic medications. The market for these drugs is expanding, with diabetes prevalence projected to reach 276.2 million by 2045. However, the side effects of glimepiride impede the growth of the market.
The 1mg segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the dosage strength, the global glimepiride dispersible tablet market is categorized as 1mg, 2mg, 3mg, 4mg, and others. Among these, the 1mg segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. The growth of this segment is accelerated by the increasing prevalence of type 2 diabetes. Effective management helps lower blood sugar levels, increase insulin levels, and prevent long-term complications like nerve problems and kidney damage. Glimepiride, formulated in dispersible tablets, is easy to administer and beneficial for geriatric patients with swallowing difficulties or deglutination disorders.
The type 2 diabetes segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the application, the global glimepiride dispersible tablet market is categorized as type 1 diabetes, type 2 diabetes, and others. Among these, the type 2 diabetes segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is driven by the increasing prevalence of type 2 diabetes, sedentary lifestyles, lack of physical activity, obesity, and the geriatric population.
The hospital pharmacies segment accounted for the greatest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global glimepiride dispersible tablet market is categorized as online pharmacies, hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment accounted for the greatest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is attributed to its focus on providing effective medicine recommendations to patients and doctors, offering compounding and dispensing facilities, and having skilled pharmacists for disease management and medication dosage regimens.
North America is expected to hold the greatest share of the global glimepiride dispersible tablet market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global glimepiride dispersible tablet market over the forecast period. The glimepiride dispersible tablet market in North America is expanding due to rising diabetes cases and healthcare expenditures. The US dominates the market due to its diabetes prevalence and geriatric population. Technological advancements, particularly in tablet formulation and targeted drug delivery systems, have contributed to the market's growth as the demand for these tablets increases.
Asia Pacific is predicted to hold the fastest-growing region of the global glimepiride dispersible tablet market throughout the estimated period. The rapid industrialization of pharmaceutical companies in the Asia Pacific is driving the growth of the market, driven by government initiatives, improved healthcare infrastructure, and the increasing demand for antidiabetic medications like glimepiride for managing type 2 diabetes.
Major key players in the global glimepiride dispersible tablet market are Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Novartis AG, Zydus Cadila, Aventis Pharma Limited, Alkem Laboratories Ltd., Hetero Drugs Ltd., Torrent Pharmaceuticals, Ltd., Biocon Limited, Sun Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Cipla Limited, Mankind Pharma Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In June 2024, Sun Pharma Laboratories received the approval from the Subject Expert Committee functional under the Central Drug Standard Control Organizations (CDSCO) to conduct the Phase IV clinical trial of the Phase IV clinical trial of the fixed dose combination (FDC) antidiabetic drug Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin plus Glimepiride plus Extended-Release Metformin Hydrochloride Tablets (10mg + 1mg + 1000mg) and (10mg + 2mg+ 1000mg) Tablets.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global glimepiride dispersible tablet market based on the below-mentioned segments:
Global Glimepiride Dispersible Tablet Market, By Dosage Strength
- 1mg
- 2mg
- 3mg
- 4mg
- Others
Global Glimepiride Dispersible Tablet Market, By Application
- Type 1 Diabetes
- Type 2 Diabetes
- Others
Global Glimepiride Dispersible Tablet Market, By Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Glimepiride Dispersible Tablet Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?